Replies to post #124937 on Biotech Values

[ghmm]

Adolor Corporation Announces Positive Results from Phase 2 Program in OIC

http://finance.yahoo.com/news/Adolor-Corporation-Announces-bw-3317825086.html?x=0&.v=1

Statistical significance (p = 0.0003) was achieved for the primary endpoint in the 0.25 mg BID dose group...with an average change from baseline in SBM frequency over the 4-week treatment period of 1.4 SBMs for the placebo group, and 2.0 and 3.4 SBMs for the 0.10 mg and 0.25 mg doses

Looks like the results are good in the high dose but the lower dose and the daily dose weren't statistically significant. Also results don't seem to be as good as NKTR-118 (which is dosed daily) I'm not as familiar with their program but guessing it was the same population.